ஜெஃப்பெரிஸ் மெய்நிகர் சுகாதாரம் மாநாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜெஃப்பெரிஸ் மெய்நிகர் சுகாதாரம் மாநாடு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜெஃப்பெரிஸ் மெய்நிகர் சுகாதாரம் மாநாடு Today - Breaking & Trending Today

Annovis Bio, Inc.: Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021


Annovis Bio, Inc.: Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021
Berwyn, Pennsylvania (Newsfile Corp. - June 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ( Annovis or the Company ), a clinical-stage drug platform company addressing Alzheimer s disease (AD), Parkinson s disease (PD) and other neurodegenerative diseases, today announced CEO Maria L. Maccecchini will present at the Jefferies Virtual Healthcare Conference 2021 as follows:
Date: Friday, June 4, 2021
Time: 8:00 a.m. ET
Webcast: https://wsw.com/webcast/jeff174/anvs/1866024
The presentation will be webcast live and archived for 30 days thereafter.
About Annovis Bio Inc.
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer s disease (AD), Parkinson s disease (PD) and Alzheimer s in Down Syndrome (AD-DS). We believe that we are the only company developing a dru ....

United States , Marial Maccecchini , Exchange Commission , Pennsylvania Newsfile Corp , Annovis Bio Inc , Redchip Companies Inc , Jefferies Virtual Healthcare Conference , Annovis Bio , Down Syndrome , Annual Report , ஒன்றுபட்டது மாநிலங்களில் , பரிமாற்றம் தரகு , ஜெஃப்பெரிஸ் மெய்நிகர் சுகாதாரம் மாநாடு , கீழ் நோய்க்குறி , ஆண்டு அறிக்கை ,

Telix to Present at the 2021 Jefferies Virtual Healthcare


About
Telix Pharmaceuticals Limited
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix’s lead investigational product, Illuccix
® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA, ....

United States , Stewart Holmstrom , Christian Behrenbruch , Telix Pharmaceuticals , Telix Corporate Communications , Australian Securities Exchange , Australian Therapeutic Goods Administration , European Union , Corporate Communications , Telix Pharmaceuticals Limited , Pharmaceuticals Limited , Chief Executive Officer , Jefferies Virtual Healthcare Conference , Molecularly Targeted Radiation , Australian Stock Exchange Tlx Ax , Telix Pharmaceuticals Limited , Christian Behrenbruch , Efferies Healthcare 2021 , Telix Pharmaceuticals , New York , ஒன்றுபட்டது மாநிலங்களில் , ஆஸ்திரேலிய பத்திரங்கள் பரிமாற்றம் , ஐரோப்பிய தொழிற்சங்கம் , பெருநிறுவன தகவல்தொடர்புகள் , மருந்துகள் வரையறுக்கப்பட்டவை , தலைமை நிர்வாகி அதிகாரி ,